Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

to leave their jobs and one patient in five takes prolonged sick leave resulting in high socio-economic and individual patient burden.

About Alitretinoin Alitretinoin is an investigational drug being developed in Phase III clinical trials by Basilea as a novel treatment for severe refractory Chronic Hand Eczema (CHE), a complex disease for which no effective treatment options are currently available. Alitretinoin has been shown to be effective in Phase II and Phase III clinical studies in patients with severe refractory CHE.

In a phase II double-blind international multi-center placebo controlled trial of 319 patients with moderate and severe chronic hand eczema refractory to topical treatment, alitretinoin was clinically effective in 29% to 53 % of patients depending on the dose administered. Alitretinoin was generally well tolerated with dose dependent headache observed as the most common side effect.

Basilea's first pivotal phase III international multi-center placebo-controlled BACH trial (Benefit of Alitretinoin in Chronic Hand eczema) showed that alitretinoin was effective in patients suffering from severe refractory CHE, as determined by the endpoint of clear and almost clear hands.

This randomized double-blind phase III pivotal study was the largest therapeutic trial ever performed in chronic hand eczema with 1,032 patients whose severe chronic disease was unresponsive to topical steroids. The patients were randomized either to a once-daily dose of 30mg or 10mg of alitretinoin, or placebo for a treatment duration of up to 24 weeks. Alitretinoin's efficacy was significantly superior to placebo in both the high and the low dose regimen. In the 30mg group 48% of patients and in the 10 mg group 28% of patients reached the primary endpoint. In this study alitretinoin was again generally well tolerated with dose dependent headache and blood lipid elevations as the most commonly observed side effects.

Alitretinoin is a teratogen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA Pharma ... its common shares have been approved for listing and trading ... ESSA will begin trading on NASDAQ on July ... TSX Venture Exchange under the symbol "EPI". As ... the NASDAQ, each of the Company,s outstanding special warrants issued ...
(Date:7/2/2015)... , July 2, 2015  Fort Lauderdale-based ... pleased to announce that its Consumer Group completed ... to Kerry Group plc (ISE: KRZ) ("Kerry"), one ... and nutrition systems, as well as functional ingredients ... pharmaceutical markets. Farlie Turner served as the exclusive ...
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... BRUNSWICK, N.J., March 8, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... President of Savient will present at the ROTH 23rd Annual ... a.m. Pacific Time.  The conference will be held at the ... A live webcast of the presentation can be accessed through ...
... Ind., March 8, 2011 Hill-Rom Holdings, Inc. (NYSE: ... as company Treasurer, effective immediately. "I am pleased ... in this role," said Mark Guinan, Senior Vice President and ... background in Treasury he will contribute to the solid financial ...
Cached Medicine Technology:
(Date:7/3/2015)... , ... July 03, 2015 , ... Talcum powder attorneys ... replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version ... lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. The site ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on ... Samir Becic emphatically declared a war on obesity in the United States. , "Obesity ... must understand the magnitude of this discovery. For that reason, I am declaring, along ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the ... was alone. He sat down to write his first poem, and three years later he ... that was special and worth sharing with the world. "I have always believed that the ...
(Date:7/2/2015)... Spring, Md. (PRWEB) , ... July 02, 2015 , ... ... mark in his solo cross-country walk to raise awareness and money for the ... and expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , A Public Briefing, Saturday, September 19, 2009 , ... , 529 14th Street, NW , Washington D.C. 20045 ... number of organizations are joining in briefings on health care reform that would ... individual rights and choices of Americans. This will provide a stark contrast ...
... UNION CITY, Calif., Sept. 9 Abaxis, Inc. (Nasdaq: ... systems, announced today that Clint Severson, chairman and chief executive officer, ... 2009 on Thursday, September 17, 2009 at 10:00 a.m. ET. The ... New York City. , , About Abaxis ...
... , , , CHICAGO, ... to the long-term care industry, today announced it was named to ... privately held companies in the United States for the third consecutive year. ... 2005 through 2008 and is the only long-term care pharmacy services provider ...
... , CHAPEL HILL, N.C., Sept. 9 TSI ... healthcare information technology, was recently recognized in Inc. Magazine,s ... nation. Some of the most successful and innovative businesses in America ... SAS, Intuit, and Nike. , , ...
... , , CINCINNATI, Sept. 9 ... know that healthful aging depends on our current habits. "Our ... take precautionary measures to strengthen ourselves," explains the women,s health expert ... are all areas that are often overlooked or taken for granted ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Joint Briefing on Proposed Health Care Reform 2Health News:Joint Briefing on Proposed Health Care Reform 3Health News:Millennium Pharmacy Systems Named to Inc. 500 for Third Consecutive Year 2Health News:TSI Healthcare Recognized by Inc. Magazine 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 3Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 4
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
... Patients who need punctal occlusion ... eye relief. They also want ... as comfortable and as unobtrusive ... Alcon punctal plugs are growing ...
10 (mm) smooth platform; Serrated handle in stainless steel....
... Only Heartlab delivers the performance ... cardiovascular information management systems. As ... and services set the benchmark. ... functionality, high-speed performance and technological ...
Medicine Products: